Concentrations of ODSH needed for inhibition of relevant steps in the pathogenesis of HIT
| Relevant reactions in HIT . | ODSH concentration with > 50% inhibition, μg/mL . | See also, Figure . |
|---|---|---|
| Inhibition of PF4 binding to platelets in the presence of 25 μg/mL free PF4 but no heparin in the fluid phase (resembling a clinical situation with strong platelet activation) | 2.08 | 1A |
| Displacement of PF4/heparin complexes from platelets with no free PF4 and no free heparin in the fluid phase | 0.52 | 1C |
| Inhibition of PF4/heparin complex binding to resting platelets in the presence of 25 μg/mL free PF4 and 0.52 μg/mL heparin in the fluid phase | 2.08 | 2 |
| Inhibition of PF4/heparin complex binding to activated platelets in the presence of 25 μg/mL free PF4 and 0.52 μg/mL heparin in the fluid phase (resembling strong platelet activation in a heparin-treated patient = worst case scenario) | 4.17 | 2 |
| Inhibition of Ab binding to PF4/heparin complexes by disruption of the covalently attached complexes | 8.33 | 3 |
| Inhibition of platelet activation by anti-PF4/heparin Abs in the presence of platelet-derived PF4 and heparin in the fluid phase | 8.33 | 4 |
| Relevant reactions in HIT . | ODSH concentration with > 50% inhibition, μg/mL . | See also, Figure . |
|---|---|---|
| Inhibition of PF4 binding to platelets in the presence of 25 μg/mL free PF4 but no heparin in the fluid phase (resembling a clinical situation with strong platelet activation) | 2.08 | 1A |
| Displacement of PF4/heparin complexes from platelets with no free PF4 and no free heparin in the fluid phase | 0.52 | 1C |
| Inhibition of PF4/heparin complex binding to resting platelets in the presence of 25 μg/mL free PF4 and 0.52 μg/mL heparin in the fluid phase | 2.08 | 2 |
| Inhibition of PF4/heparin complex binding to activated platelets in the presence of 25 μg/mL free PF4 and 0.52 μg/mL heparin in the fluid phase (resembling strong platelet activation in a heparin-treated patient = worst case scenario) | 4.17 | 2 |
| Inhibition of Ab binding to PF4/heparin complexes by disruption of the covalently attached complexes | 8.33 | 3 |
| Inhibition of platelet activation by anti-PF4/heparin Abs in the presence of platelet-derived PF4 and heparin in the fluid phase | 8.33 | 4 |
ODSH indicates 2-O, 3-O desulfated heparin; HIT, heparin-induced thrombocytopenia; and PF, platelet factor.